Search

Your search keyword '"An, W."' showing total 47,583 results

Search Constraints

Start Over You searched for: Author "An, W." Remove constraint Author: "An, W." Journal blood Remove constraint Journal: blood
47,583 results on '"An, W."'

Search Results

1. Detection and Prevention of ADAR1p150-Induced Hematopoietic Stem and Progenitor Cell Aging

2. Germ line ERG haploinsufficiency defines a new syndrome with cytopenia and hematological malignancy predisposition

3. Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study)

4. A genetic association study of circulating coagulation factor VIII and von Willebrand factor levels

5. Clinical and functional spectrum of RAC2-related immunodeficiency

6. NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLLr B-ALL by regulating NR3C1 expression

8. Soluble glycoprotein VI predicts abdominal aortic aneurysm growth rate and is a novel therapeutic target

10. Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL

11. HA-1–targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation

12. Genome-wide transcription factor–binding maps reveal cell-specific changes in the regulatory architecture of human HSPCs

13. Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

14. Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study

15. Adaptation to ex vivo culture reduces human hematopoietic stem cell activity independently of the cell cycle

16. ABBV-319: a CD19-targeting glucocorticoid receptor modulator antibody-drug conjugate therapy for B-cell malignancies

17. Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study

18. Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial

19. A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome

20. Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL

21. Genetic subdivisions of follicular lymphoma defined by distinct coding and noncoding mutation patterns

22. Factor VIII trafficking to CD4+ T cells shapes its immunogenicity and requires several types of antigen-presenting cells

23. Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma

26. Type 1 VWD classification revisited: novel insights from combined analysis of the LoVIC and WiN studies

30. Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population

32. B Cell-Restricted Depletion of Dnmt3a Activates Notch Signaling and Causes Chronic Lymphocytic Leukemia

36. CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS

37. The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma

38. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma

40. Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study

41. Recurrent CLTC::SYK fusions and CSF1R mutations in juvenile xanthogranuloma of soft tissue

42. Disruption of cotranscriptional splicing suggests RBM39 is a therapeutic target in acute lymphoblastic leukemia

44. Whole-genome analysis of plasma fibrinogen reveals population-differentiated genetic regulators with putative liver roles

47. Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy

48. Natural history study of patients with familial platelet disorder with associated myeloid malignancy

49. Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD

50. Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG

Catalog

Books, media, physical & digital resources